AMPH - Amphastar Pharmaceuticals Inc Stock Price, Fair Value and News

40.01USD+1.36 (+3.52%)Market Closed

Market Summary

USD40.01+1.36

Market Closed

3.52%

AMPH Stock Price

View Fullscreen

AMPH RSI Chart

AMPH Valuation

Market Cap

1.9B

Price/Earnings (Trailing)

13.99

Price/Sales (Trailing)

2.99

EV/EBITDA

10.59

Price/Free Cashflow

13.24

AMPH Price/Sales (Trailing)

AMPH Profitability

Operating Margin

54.49%

EBT Margin

26.59%

Return on Equity

21.51%

Return on Assets

9.09%

Free Cashflow Yield

7.55%

AMPH Fundamentals

AMPH Revenue

Revenue (TTM)

644.4M

Rev. Growth (Yr)

31.91%

Rev. Growth (Qtr)

-1.36%

AMPH Earnings

Earnings (TTM)

137.5M

Earnings Growth (Yr)

6.65%

Earnings Growth (Qtr)

-26.52%

Breaking Down AMPH Revenue

Last 7 days

1.0%

Last 30 days

-9.1%

Last 90 days

-27.3%

Trailing 12 Months

-7.0%

How does AMPH drawdown profile look like?

AMPH Financial Health

Current Ratio

2.17

Debt/Equity

0.92

Debt/Cashflow

0.31

AMPH Investor Care

Shares Dilution (1Y)

0.42%

Diluted EPS (TTM)

2.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	518.6M	540.9M	601.3M	644.4M
2022	455.1M	476.9M	484.9M	499.0M
2021	368.2M	384.0M	412.8M	437.8M
2020	327.3M	334.0M	337.3M	349.8M
2019	316.1M	324.1M	328.7M	322.4M
2018	241.9M	247.8M	265.4M	294.7M
2017	252.5M	249.6M	243.3M	240.2M
2016	254.0M	268.2M	268.5M	255.2M
2015	221.5M	226.3M	230.5M	251.5M
2014	222.6M	209.1M	209.5M	210.5M
2013	210.7M	217.0M	223.3M	229.7M
2012	0	0	0	204.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amphastar Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	petersen floyd f.	sold	-21,714	43.4283	-500	-
Mar 17, 2024	zhou rong	sold (taxes)	-84,421	43.05	-1,961	senior evp, production center
Mar 17, 2024	zhang jack y.	sold (taxes)	-303,589	43.05	-7,052	ceo & chief scientific officer
Mar 17, 2024	zhang jack y.	sold (taxes)	-678,812	43.05	-15,768	ceo & chief scientific officer
Mar 17, 2024	liawatidewi yakob	sold (taxes)	-74,304	43.05	-1,726	evp corp admin center
Mar 17, 2024	peters william j	sold (taxes)	-183,178	43.05	-4,255	cfo, evp & treasurer
Mar 16, 2024	peters william j	sold (taxes)	-219,770	43.05	-5,105	cfo, evp & treasurer
Mar 16, 2024	liawatidewi yakob	sold (taxes)	-71,936	43.05	-1,671	evp corp admin center
Mar 16, 2024	zhou rong	sold (taxes)	-101,383	43.05	-2,355	senior evp, production center
Mar 15, 2024	peters william j	sold (taxes)	-98,369	43.05	-2,285	cfo, evp & treasurer

Which funds bought or sold AMPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	-503	1,229	-%
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-60.00	-222	88.00	-%
Apr 18, 2024	McGlone Suttner Wealth Management, Inc.	sold off	-100	-28,018	-	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	61.87	368,056	2,835,000	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-2,000	4,000	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	reduced	-26.85	-334,629	361,555	0.02%
Apr 17, 2024	Trivant Custom Portfolio Group, LLC	unchanged	-	-3,588	8,782	0.01%
Apr 17, 2024	GUIDANCE CAPITAL, INC	reduced	-43.71	-588,115	343,245	0.13%
Apr 16, 2024	Stratos Wealth Partners, LTD.	reduced	-20.7	-187,219	241,154	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	sold off	-100	-1,326,060	-	-%

Are Funds Buying or Selling AMPH?

Are funds buying AMPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMPH

No. of Funds

Unveiling Amphastar Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	federated hermes, inc.	4.52%	2,165,071	SC 13G/A
Feb 13, 2024	vanguard group inc	5.88%	2,814,710	SC 13G/A
Feb 09, 2024	zhang jack y.	26.2%	13,435,210	SC 13G/A
Jan 23, 2024	blackrock inc.	12.6%	6,037,158	SC 13G/A
Jan 17, 2024	federated hermes, inc.	6.83%	3,272,761	SC 13G/A
Feb 09, 2023	vanguard group inc	5.42%	2,621,807	SC 13G/A
Feb 01, 2023	federated hermes, inc.	6.80%	3,284,217	SC 13G/A
Jan 27, 2023	zhang jack y.	25.5%	13,110,695	SC 13G/A
Jan 26, 2023	blackrock inc.	14.6%	7,038,769	SC 13G/A
Jan 20, 2023	blackrock inc.	14.6%	7,038,769	SC 13G/A

Recent SEC filings of Amphastar Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	DEFA14A	DEFA14A
Apr 12, 2024	ARS	ARS
Apr 12, 2024	DEF 14A	DEF 14A
Apr 12, 2024	DEFA14A	DEFA14A
Apr 02, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Amphastar Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	356.3B	85.2B	-5.03%	-9.57%	10.14	4.18	6.46%	95.94%
MRK	318.7B	60.1B	1.61%	10.23%	873.24	5.3	1.40%	-97.49%
PFE	146.8B	46.5B	-6.17%	-34.78%	-105.7	3.15	42.59%	-114.62%
AMGN	144.1B	28.2B	-1.51%	10.46%	21.46	5.11	7.09%	2.52%
GILD	83.2B	27.1B	-9.77%	-21.18%	14.68	3.07	-0.60%	23.36%
TEVA	14.4B	15.8B	-4.60%	54.01%	-25	0.91	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	-1.63%	-14.16%	-328.55	0.9	4.58%	90.97%
ALKS	4.0B	1.7B	-13.93%	-17.76%	11.2	2.4	49.61%	324.78%
BHC	3.2B	8.8B	-9.38%	13.00%	-5.36	0.36	7.79%	-163.11%
AMPH	1.9B	644.4M	-9.13%	-7.04%	13.99	2.99	29.14%	50.51%
SMALL-CAP
TLRY	1.3B	743.2M	-12.63%	-26.38%	-3.8	1.8	24.65%	80.36%
TXMD	21.6M	1.3M	-20.43%	-49.32%	-2.1	16.56	-98.14%	-109.18%
ACRX	16.6M	-	-10.09%	36.11%	-0.9	0.22	2882.68%	-138.52%
AGRX	2.6M	19.6M	-34.48%	-94.22%	-0.18	0.13	80.00%	43.08%
ACOR	472.0K	117.6M	-96.45%	-95.94%	0	0	-0.79%	-283.60%

Amphastar Pharmaceuticals Inc News

Latest updates

Amphastar Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-1.4%	178	181	146	140	135	120	123	120	121	112	102	103	96.00	83.00	86.00	85.00	83.00	80.00	79.00	80.00	90.00
Cost Of Revenue	13.6%	82.00	72.00	73.00	66.00	64.00	62.00	60.00	65.00	65.00	61.00	54.00	58.00	59.00	47.00	53.00	48.00	50.00	45.00	47.00	49.00	55.00
Gross Profit	-11.3%	96.00	108	73.00	74.00	71.00	59.00	63.00	56.00	56.00	51.00	47.00	45.00	37.00	37.00	33.00	37.00	33.00	35.00	32.00	31.00	35.00
Operating Expenses	18.0%	42.00	36.00	36.00	40.00	33.00	35.00	39.00	34.00	32.00	26.00	37.00	35.00	34.00	33.00	36.00	29.00	34.00	33.00	31.00	34.00	33.00
S&GA Expenses	34.5%	9.00	6.00	7.00	7.00	5.00	5.00	6.00	6.00	4.00	5.00	4.00	5.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00
R&D Expenses	22.5%	20.00	17.00	17.00	20.00	17.00	19.00	23.00	16.00	17.00	11.00	18.00	15.00	18.00	18.00	16.00	15.00	20.00	19.00	16.00	15.00	17.00
EBITDA Margin	-2.6%	0.35*	0.36*	0.30*	0.28*	0.28*	0.26*	0.29*	0.29*	0.24*	0.18*	0.11*	0.07*	-	-	-	-	-	-	-	-	-
Interest Expenses	-31.0%	9.00	14.00	4.00	0.00	1.00	1.00	0.00	0.00	0.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	-66.7%	5.00	14.00	6.00	7.00	7.00	7.00	6.00	4.00	7.00	7.00	6.00	1.00	-0.95	2.00	-0.07	2.00	0.00	1.00	14.00	-1.48	-1.13
Earnings Before Taxes	-35.0%	41.00	64.00	33.00	34.00	41.00	23.00	23.00	29.00	27.00	38.00	14.00	5.00	-6.74	7.00	-1.50	6.00	1.00	2.00	61.00	-3.63	1.00
EBT Margin	-6.6%	0.27*	0.28*	0.24*	0.23*	0.23*	0.21*	0.25*	0.24*	0.19*	0.12*	0.05*	0.01*	-	-	-	-	-	-	-	-	-
Net Income	-26.5%	36.00	49.00	26.00	26.00	34.00	16.00	17.00	24.00	20.00	30.00	8.00	5.00	-6.27	4.00	-0.19	4.00	-1.03	1.00	48.00	1.00	2.00
Net Income Margin	-5.1%	0.21*	0.22*	0.19*	0.18*	0.18*	0.16*	0.19*	0.18*	0.14*	0.09*	0.03*	0.01*	-	-	-	-	-	-	-	-	-
Free Cashflow	-73.4%	14.00	54.00	46.00	31.00	9.00	15.00	-3.15	45.00	34.00	-4.65	26.00	15.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-2.1%	1,513	1,545	1,378	774	742	727	724	716	672	652	666	646	631	614	600	573	587	586	601	545	514
Current Assets	-9.8%	490	543	385	408	378	384	377	364	318	304	311	300	280	277	267	247	255	269	284	230	220
Cash Equivalents	-45.9%	144	267	149	177	156	157	166	173	127	107	125	102	95.00	90.00	89.00	57.00	76.00	87.00	122	81.00	88.00
Inventory	-3.8%	106	110	105	104	104	103	99.00	95.00	93.00	100	98.00	97.00	97.00	109	105	108	111	110	99.00	79.00	69.00
Net PPE	0.7%	283	281	279	243	238	233	238	243	244	243	253	253	260	246	238	231	234	222	220	215	210
Liabilities	-8.0%	873	949	789	225	213	222	224	237	226	222	199	195	183	163	158	149	159	152	169	164	149
Current Liabilities	-12.6%	225	258	251	106	95.00	102	104	114	104	98.00	125	127	112	97.00	93.00	83.00	90.00	87.00	101	112	107
Long Term Debt	-7.6%	590	638	488	73.00	73.00	74.00	74.00	74.00	75.00	76.00	30.00	32.00	34.00	33.00	35.00	36.00	39.00	38.00	40.00	31.00	32.00
Shareholder's Equity	7.4%	639	595	589	549	529	505	499	480	446	430	467	451	449	451	442	423	428	434	432	380	364
Retained Earnings	9.7%	409	373	324	298	272	238	222	205	180	161	131	123	118	124	120	120	116	117	116	68.00	67.00
Additional Paid-In Capital	1.7%	486	478	471	457	455	449	443	433	422	413	427	414	410	404	397	371	367	362	355	349	344
Shares Outstanding	0.4%	48.00	48.00	49.00	48.00	48.00	49.00	49.00	48.00	48.00	48.00	48.00	48.00	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	45.00	45.00	46.00	46.00	45.00	46.00	46.00	44.00	44.00	45.00	32.00
Float	-	-	-	1,487	-	-	-	885	-	-	-	482	-	-	-	567	-	-	-	638	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-62.9%	23,864	64,334	54,923	40,382	15,226	20,375	2,815	50,765	40,441	2,569	32,159	22,825	16,893	8,807	30,089	1,477	5,652	-12,003	51,723	-3,610	9,517
Share Based Compensation	-0.5%	4,622	4,644	4,865	6,111	4,304	4,299	4,235	5,022	3,850	3,919	6,084	4,834	4,333	4,370	6,513	5,282	4,295	4,294	4,032	4,674	3,910
Cashflow From Investing	-230.8%	-103,049	-31,152	-508,582	-6,333	-229	-15,258	-8,180	-9,110	-11,954	-3,769	-4,254	-8,695	-12,176	-5,451	-10,066	-8,722	-7,352	-18,622	-9,669	-14,884	-8,797
Cashflow From Financing	-154.4%	-47,083	86,613	428,111	-13,548	-16,162	-13,931	-994	4,648	-8,696	-16,492	-5,191	-6,639	-227	-3,026	12,456	-11,449	-10,382	-3,888	-742	11,229	16,922
Buy Backs	-100.0%	-	50,001	128	8,015	18,069	14,494	6,117	1,229	13,436	6,093	5,561	3,783	3,390	4,329	5,756	10,950	13,777	4,426	1,073	3,015	2,607

AMPH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net Revenues:
Total net revenues	$ 644,395	$ 498,987	$ 437,768
Cost of revenues	293,274	250,127	238,029
Gross profit	351,121	248,860	199,739
Operating expenses:
Selling, distribution, and marketing	28,853	21,531	17,486
General and administrative	51,540	45,061	51,434
Research and development	73,741	74,771	60,932
Total operating expenses	154,134	141,363	129,852
Income from operations	196,987	107,497	69,887
Non-operating income (expenses):
Interest income	5,459	1,321	601
Interest expense	(27,158)	(1,846)	(885)
Other income (expenses), net	(3,929)	9,068	14,536
Total non-operating income (expenses), net	(25,628)	8,543	14,252
Income before income taxes	171,359	116,040	84,139
Income tax provision	31,833	23,477	20,630
Income before equity in losses of unconsolidated affiliate	139,526	92,563	63,509
Equity in losses of unconsolidated affiliates	(1,981)	(1,177)	(208)
Net income attributable to Amphastar Pharmaceuticals, Inc.	137,545	91,386	63,301
Net income attributable to non-controlling interests			1,185
Net income attributable to Amphastar Pharmaceuticals, Inc.	$ 137,545	$ 91,386	$ 62,116
Net income per share
Basic (in Dollars per share)	$ 2.85	$ 1.88	$ 1.30
Diluted (in Dollars per share)	$ 2.60	$ 1.74	$ 1.25
Weighted-average shares used to compute net income per shares
Basic (in Shares)	48,265	48,551	47,777
Diluted (in Shares)	53,001	52,427	49,784
Product revenues, net
Net Revenues:
Total net revenues	$ 593,238	$ 498,987	$ 437,768
Other revenues
Net Revenues:
Total net revenues	$ 51,157

AMPH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 144,296	$ 156,098
Restricted cash	235	235
Short-term investments	112,510	19,664
Restricted short-term investments	2,200	2,200
Accounts receivable, net	114,943	88,804
Inventories	105,833	103,584
Income tax refunds and deposits	526	171
Prepaid expenses and other assets	9,057	7,563
Total current assets	489,600	378,319
Property, plant, and equipment, net	282,746	238,266
Finance lease right-of-use assets	564	753
Operating lease right-of-use assets	32,333	25,554
Investment in unconsolidated affiliate	527	2,414
Goodwill and intangible assets, net	613,295	37,298
Long-term investments	14,685
Other assets	25,910	20,856
Deferred tax assets	53,252	38,527
Total assets	1,512,912	741,987
Current liabilities:
Accounts payable and accrued liabilities	93,366	84,242
Accrued payments for BAQSIMI	126,090
Income taxes payable	1,609	4,571
Current portion of long-term debt	436	3,046
Current portion of operating lease liabilities	3,906	3,003
Total current liabilities	225,407	94,862
Long-term reserve for income tax liabilities	6,066	7,225
Long-term debt, net of current portion and unamortized debt issuance costs	589,579	72,839
Long-term operating lease liabilities, net of current portion	29,721	23,694
Deferred tax liabilities		144
Other long-term liabilities	22,718	14,565
Total liabilities	873,491	213,329
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding
Common stock: par value $0.0001; 300,000,000 shares authorized; 59,390,194 and 48,068,881 shares issued and outstanding as of December 31, 2023 and 58,110,231 and 48,112,069 shares issued and outstanding as of December 31, 2022, respectively	6	6
Additional paid-in capital	486,056	455,077
Retained earnings	409,268	271,723
Accumulated other comprehensive loss	(8,478)	(8,624)
Treasury stock	(247,431)	(189,524)
Total equity	639,421	528,658
Total liabilities and stockholders' equity	$ 1,512,912	$ 741,987

About Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

CEO	Dr. Yongfeng Zhang Ph.D.
WEBSITE	amphastar.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	1615

Amphastar Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Amphastar Pharmaceuticals Inc? What does AMPH stand for in stocks?

AMPH is the stock ticker symbol of Amphastar Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amphastar Pharmaceuticals Inc (AMPH)?

As of Fri Apr 19 2024, market cap of Amphastar Pharmaceuticals Inc is 1.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers.

What is the fair value of AMPH stock?

You can check AMPH's fair value in chart for subscribers. The fair value of Amphastar Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amphastar Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amphastar Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether AMPH is over valued or under valued. Whether Amphastar Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Amphastar Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMPH.

What is Amphastar Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, AMPH's PE ratio (Price to Earnings) is 13.99 and Price to Sales (PS) ratio is 2.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMPH PE ratio will change depending on the future growth rate expectations of investors.